Actively Recruiting
A Study Of Moderately Hypo-Fractionated External-beam Radiotherapy With Concurrent Chemotherapy and High Dose Rate Brachytherapy In Cervical Cancer
Led by Ain Shams University · Updated on 2026-01-15
30
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Cancer of the uterine cervix is one of the most common gynecologic cancer diagnosis and cause of death among gynecologic cancers worldwide .The two major histologic types of cervical cancer are squamous cell carcinoma, adenocarcinoma and the preinvasive disease that corresponds with these histologies share many of the same risk factors . Cancer cervix can be treated definitively with concurrent chemoradiation (external beam radiotherapy and chemotherapy) followed by high dose rate brachytherapy. Treatment duration can be shortened by increasing the dose per fraction of treatment, which can improve survival rates, reduce the risk of treatment failure, reduce costs and patient exposure.
CONDITIONS
Official Title
A Study Of Moderately Hypo-Fractionated External-beam Radiotherapy With Concurrent Chemotherapy and High Dose Rate Brachytherapy In Cervical Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- FIGO IB1 cervical cancer if not surgical candidate, amenable to chemoradiotherapy
- FIGO stage IB2, IB3, IIA, or IIB cervical cancer
- FIGO stage IIIA or IIIB cervical cancer
- FIGO stage IIIC1 cervical cancer with largest suspicious pelvic node less than 3 cm, fewer than 3 suspicious nodes, and no suspicious common iliac nodes
- Histologically confirmed invasive uterine cervical carcinoma of squamous cell, adenocarcinoma, or adenosquamous cell types
- Candidate for definitive chemoradiotherapy with weekly cisplatin (creatinine clearance >60 ml/min) or carboplatin AUC 2 if cisplatin not tolerated (creatinine clearance 40-60 ml/min)
- Candidate for brachytherapy
- ECOG performance status up to 2
You will not qualify if you...
- FIGO stage IA, IIIC2, IVA, or IVB cervical cancer
- FIGO stage IIIC1 with node size ≥3 cm, common iliac node involvement, or more than 2 suspicious nodes
- Previous pelvic or abdominal radiotherapy
- Active inflammatory bowel disease
- Active connective tissue disorders (e.g., scleroderma, systemic lupus erythematous)
- Unable to undergo MRI scan
- ECOG performance status of 3 or higher
- Creatinine clearance less than 40 ml/min
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ainshams University
Cairo, Cairo Governorate, Egypt
Actively Recruiting
Research Team
M
Manar Adel, master degree
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here